Lower limb function and quality of life after ILP for soft-tissue sarcoma

[1] Bottomley A(2003)The challenges and achievements involved in implementing quality of life research in cancer clinical trials Eur J Cancer 39 275-85

[2] Vanvoorden V(2014)Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection J Surg Oncol 109 786-90

[3] Flechtner H(2012)Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity Ann Surg Oncol 19 1800-7

[4] Therasse P(2012)Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients J Surg Oncol 105 563-9

[5] Jakob J(2006)Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma Cancer 106 1776-84

[6] Tunn PU(2005)Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 16 1061-8

[7] Hayes AJ(1996)Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial J Clin Oncol 14 2653-65

[8] Pilz LR(2016)Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma Int J Hyperthermia 32 159-64

[9] Nowak K(2012)Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas Eur J Surg Oncol 39 61-7

[10] Hohenberger P(2011)Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan J Surg Oncol 103 371-9

[1] Bottomley A(2003)The challenges and achievements involved in implementing quality of life research in cancer clinical trials Eur J Cancer 39 275-85

[2] Vanvoorden V(2014)Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection J Surg Oncol 109 786-90

[3] Flechtner H(2012)Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity Ann Surg Oncol 19 1800-7

[4] Therasse P(2012)Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients J Surg Oncol 105 563-9

[5] Jakob J(2006)Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma Cancer 106 1776-84

[6] Tunn PU(2005)Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 16 1061-8

[7] Hayes AJ(1996)Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial J Clin Oncol 14 2653-65

[8] Pilz LR(2016)Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma Int J Hyperthermia 32 159-64

[9] Nowak K(2012)Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas Eur J Surg Oncol 39 61-7

[10] Hohenberger P(2011)Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan J Surg Oncol 103 371-9